High-Dose Aflibercept 8 mg Demonstrates Sustained Visual Gains and Durability in Polypoidal Choroidal Vasculopathy
Introduction and Highlights
The management of neovascular age-related macular degeneration (nAMD) has been revolutionized by anti-vascular endothelial growth factor (VEGF) therapies. However, polypoidal choroidal vasculopathy (PCV), a distinct clinical entity often considered a subtype of nAMD, presents unique therapeutic challenges, particularly in Asian populations where its prevalence is significantly higher. The PULSAR randomized clinical trial recently evaluated the efficacy of a high-dose (8 mg) formulation of aflibercept compared to the standard 2 mg dose. This post hoc analysis specifically scrutinizes the outcomes for the subgroup of patients diagnosed with PCV.
Key Highlights
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.